Cello Health PLC (LON:CLL)

Cello Health PLC (LON:CLL)


Share Price
124.00 p
Change
-1.5 (-1.20 %)
Market Cap
£130.34 m
Proactive Investors - Run By Investors For Investors

Cello Health PLC RNS Release

Director/PDMR Shareholding


RNS Number : 6335T
Cello Health PLC
21 March 2019
 

21 March 2019

 

Cello Health plc

("Cello" or the "Group")

Director/PDMR Shareholding

 

The Group provides the following notification in accordance with Article 19(3) of the Market Abuse Regulation:

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Alasdair Combe

2

Reason for the notification

a)

Position/status

Person closely associated with Jane Shirley, Joint CEO of Cello Health Insight and CEO of Cello Health Europe

b)

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Cello Health plc

b)

LEI

2138004TZYGZLWQP7N64 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 10 pence each

Identification code

ISIN: GB00B0310763

b)

Nature of the transaction

Purchase of ordinary shares

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




122.5 pence

5,000







d)

 

Aggregated information


- Aggregated volume

5,000

- Price

£6,125.00

e)

Date of the transaction

21 March 2019

f)

Place of the transaction

AIMX

 

Enquiries:

 

Cello Health plc

020 7812 8460

Mark Scott, Chief Executive


Mark Bentley, Finance Director




Cenkos Securities plc

0207 397 8900

Mark Connelly

Harry Hargreaves




 

Notes to Editors

Cello Health plc is a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. Cello Health plc currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.

Cello Health plc enables clients to commercialise and differentiate their assets and drive brand success in ever more complex global markets. The business delivers its services through nearly 1,000 highly skilled professionals, utilising latest thinking, technology and digital solutions.

Cello Health plc delivers its services from an office network in the UK, USA, and Asia, with hub offices in New York City, Philadelphia PA, London, Edinburgh, Farnham and Cheltenham.

For further information, please visit: https://cellohealthplc.com


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHCKDDKPBKDFNB

Cello Health PLC Timeline

Video
April 11 2019
Big Picture
March 22 2019

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use